Pharmaceutical

Biogen’s higher Spinraza dose shows better efficacy in Phase II/III trial 

Biogen plans to apply for regulatory approval of this investigational dose regimen following positive trial data.

Sep 8, 2024 - 04:00
Biogen’s higher Spinraza dose shows better efficacy in Phase II/III trial 
Biogen plans to apply for regulatory approval of this investigational dose regimen following positive trial data.
Read the original article

Tags:

Previous Article

Onward awarded $1.1M grant from the Christopher & Dana Reeve Foundation to advan...

Next Article

After failed FSGS bid, Travere wins full FDA approval for Filspari in IgAN

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Otsuka and Astex’s oral Inaqovi wins European approval for AML

Otsuka and Astex’s oral Inaqovi wins European approval ...

Sep 19, 2023

Bayer expands German manufacturing facilities to fulfill supply demand

Bayer expands German manufacturing facilities to fulfil...

Nov 24, 2023

Eli Lilly’s anti-vanity ad campaign for Oscars

Eli Lilly’s anti-vanity ad campaign for Oscars

Mar 8, 2024